Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Treatment with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ resulted in patients with persistent atrial fibrillation experiencing an improved quality of life The catheter is part of Abbott's suite of electrophysiology solutions designed to improve procedures to address cardiac arrythmias ABBOTT PARK, Ill., April 29, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the PERSIST-END study, which showed that nearly nine out of 10 patients (89%) treated for persistent atrial fibrillation (AFib) with the company's TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) remained symptom-free for up to 15 months following the procedure.

Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months

Intuitive Surgical

Pfizer

UnitedHealth Group

Walgreens

People will always need medical treatment regardless of what is going on with the economy, which makes stocks in the healthcare sector consistently reliable investments.

The 5 Best Healthcare Stocks To Own Right Now

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., Abbott's steerable sheath offers precise and flexible placement when used with the company's Amplatzer Amulet LAA Occluder ABBOTT PARK, Ill., April 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. availability of its Amplatzer™ Steerable Delivery Sheath, which is used with the company's Amplatzer Amulet™ Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.

Abbott Strengthens Left Atrial Appendage Closure Leadership With U.S. Availability of Amplatzer™ Steerable Delivery Sheath for the Company's Amulet™ Device

Meta-analysis of 75 real-world studies found that Abbott's FreeStyle Libre system is associated with significant reductions in glycated hemoglobin (HbA1c) at three months1 Reductions in HbA1c followed a similar pattern in people with both type 1 and type 2 diabetes and were sustained for up to 24 months1 Meta-analysis shows that people with type 2 diabetes who use insulin benefit from the FreeStyle Libre system in the same way as people with type 1 diabetes in real-world studies1, showing the need for access to the latest glucose monitoring technology ABBOTT PARK, Ill., April 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from a new meta-analysis of 75 real-world, observational studies demonstrating that its FreeStyle® Libre system provides significant reductions in glycated hemoglobin (HbA1c) that are sustained up to 24 months in adults with both type 1 and type 2 diabetes.1 People with type 2 diabetes who use insulin are often restricted when it comes to access to continuous glucose monitoring, but both clinical trials and real-world studies demonstrate significant improvement of glycemic control.

New Analysis Shows that Abbott's FreeStyle Libre® System Provides Similar and Sustained Reductions in Glucose Levels for People with Both Type 1 and Type 2 Diabetes

The three companies will work to accelerate development of automated insulin delivery system for people living with diabetes System is being designed to include Abbott's FreeStyle Libre® 3 sensor, CamDiab's CamAPS FX algorithm, and Ypsomed's mylife™ YpsoPump® Partnership demonstrates the companies' collective desire to drive integrated solutions to help people with diabetes better manage their condition and improve health outcomes BARCELONA, Spain, April 27, 2022 /PRNewswire/ -- Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes. The initial focus of the partnership will be in European countries.

Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes

ABBOTT PARK, Ill., April 26, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation (TRC) to purchase up to 1,000,000 Abbott common shares, representing approximately 0.06% of the company's outstanding shares.

Abbott Recommends Rejection of Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

There's some sunshine around the dark cloud.

Here's the Worst News for Abbott Right Now (and Why Investors Shouldn't Worry)

Alcon Inc. - Registered Shares

Cardiovascular Systems

Zimmer Biomet Hlds

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.

3 Medical Product Stocks Poised to Beat This Earnings Season

Now available for use with both Apple and Android devices, the app helps people track pain relief during the treatment journey with neurostimulation devices Updated app provides doctors with an at-a-glance assessment of their patients while on their treatment journey ABBOTT PARK, Ill., April 25, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has launched an upgraded version of its NeuroSphere™ myPath™ digital health app with enhanced functionality that will help doctors more closely track their patients as they trial Abbott neurostimulation devices to address their chronic pain.

Abbott Strengthens Its Connected Care Technologies with Latest NeuroSphere™ myPath™ Digital Health App

Will sales plummet once the coronavirus shifts from being a pandemic-level threat to an endemic illness?

21 Bold Words from Abbott's CEO About the Future of Its COVID Tests

Abbot (NYSE: ABT) records a first-quarter EPS of $1.73, beating analyst estimates of $1.47 by 25 cents. The company recorded a first-quarter revenue of about $11.9 billion, which also topped the $11.02 billon consensus estimate.

Abbot tops first-quarter EPS by $0.26

Deere & Company

Lam Research

NIKE

Nucor

QUALCOMM

Some analysts believe that the market may have seen peak inflation. Here are seven stocks to buy if inflation is at, or near, its peak The post 7 Stocks to Buy If You Think Inflation Is Topping Out appeared first on InvestorPlace.

7 Stocks to Buy If You Think Inflation Is Topping Out

Make the most of your money by investing in this top income stock.

Got $5,000? This Dividend King Is Down More Than 15% This Year

Abbott Laboratories reported its financial results for the first quarter on Wednesday. Here's what you should know.

Abbott Laboratories reports a 14% YoY increase in Q1 sales

Abbott stock climbed Wednesday as it reported quarterly results that beat estimates, driven by $3.3 billion in sales of its Covid-19 tests. The post Abbott Labs First-Quarter Results Top Estimates, Earnings Outlook Short appeared first on Investor's Business Daily.

Abbott Labs First-Quarter Results Top Estimates, Earnings Outlook Short

Abbott Laboratories, the maker of the popular rapid BinaxNow COVID-19 test, made $3.3 billion in revenue from its COVID-19 tests in the first three months of the year, far surpassing the $2.5 billion in COVID-19 tests that the company predicted it would sell over the entirety of 2022.

Abbott predicts fewer sales of COVID-19 tests in 2022 but says the business of at-home tests isn't going away

Abbott Laboratories (NYSE:ABT ) Q1 2022 Earnings Conference Call April 20, 2022 9:00 AM ET Company Participants Scott Leinenweber - Vice President, Investor Relations, Licensing and Acquisition Robert Ford - Chairman and Chief Executive Officer Bob Funck - Executive Vice President Finance and Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Josh Jennings - Cowen and Company Larry Biegelsen - Wells Fargo Joanne Wuensch - Citigroup Travis Steed - Bank of America Matt Miksic - Credit Suisse Operator Good morning, and thank you for standing by. Welcome to Abbott's First Quarter 2022 Earnings Conference Call.

Abbott Laboratories (ABT) CEO Robert Ford on Q1 2022 Results - Earnings Call Transcript

Within Adult Nutrition, Abbott (ABT) gains from the strong performance of Ensure and Glucerna brands in Q1.

Abbott's (ABT) Q1 Earnings and Revenues Exceed Estimates

Abbott Laboratories (NYSE: ABT) is not in danger of losing its business but we have some concerns its share price could fall. Not only is it a highly-valued stock compared to peers but its current revenue and earnings are based largely on COVID-19.

Highly Valued Abbot Laboratories Could Move Lower

Abbott (ABT) delivered earnings and revenue surprises of 17.69% and 7.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Surpasses Q1 Earnings and Revenue Estimates

Abbott Laboratories (NYSE: ABT) has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50. Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02.

Abbott Clocks Q1 COVID-19 Test Sales Of $3.3B, Reaffirms FY22 EPS Outlook

The medical devices company reported sales of $11.9 billion for the quarter.

Abbott Beats Expectations, but Doesn't Expect Covid-19 Test Sales to Last

Shares of Abbott Laboratories ABT, +3.17% were down 2.0% in premarket trading on Wednesday though the company beat earnings and revenue expectations in the first quarter of 2022, driven in large part by more than $3 billion in sales of its COVID-19 tests. Abbott had earnings of $2.4 billion, or $1.37 per share, in the first quarter of 2022, up from $1.8 billion, or $1.00 per share, in the same quarter a year ago.

Abbott reported $3.3 billion in sales of COVID-19 tests in the first quarter

Abbott Laboratories reported a 36% rise in quarterly profit on Wednesday, boosted by an Omicron-led demand for its COVID-19 test kits and a recovery in elective procedures, which boosted demand for its medical devices.The company's net earnings rose to $2.45 billion, or $1.37 per share, in the first quarter ended March 31, from $1.8 billion, or $1 per share, a year earlier.

Abbott reports 36% rise in quarterly profit on Omicron-driven testing demand

Sales growth of 13.8 percent; organic sales growth of 17.5 percent Global COVID-19 testing-related sales of $3.3 billion in the first quarter Excluding COVID-19 testing-related sales, first-quarter reported sales growth of 3.9 percent and organic sales growth of 7.7 percent GAAP diluted EPS growth of 37.0 percent; adjusted diluted EPS growth of 31.1 percent Continues to strengthen portfolio with new product approvals and expanded reimbursement coverage ABBOTT PARK, Ill., April 20, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2022.

News for Abbott Labs Stock (ABT)